Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection

Massimo Amicosante; Fabrizio Poccia; Cristiana Gioia; Carla Montesano; Simone Topino; Federico Martini; Pasquale Narciso; Leopoldo P. Pucillo; Gianpiero D'Offizi

doi:10.1086/377454

Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection

Massimo Amicosante, Fabrizio Poccia, Cristiana Gioia, Carla Montesano, Simone Topino, Federico Martini, Pasquale Narciso, Leopoldo P. Pucillo, Gianpiero D'Offizi

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Research output: Contribution to journal › Article › peer-review

Abstract

Structured treatment interruption (STI) may help to alleviate the problems associated with long-term antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients. We analyzed the role that baseline levels of cytokines in plasma play as markers of a favorable outcome of STI. Two groups of patients were defined: STI responders and STI nonresponders. STI responders showed a higher baseline concentration of interleukin (IL)-15 in plasma than did STI nonresponders and showed lower levels of tumor necrosis factor (TNF)-α during STI. No differences were observed in levels of IL-2, IL-7, or interferon-α in plasma. Our data show that (1) levels of TNF-α in plasma correlate with HIV viremia and (2) monitoring baseline levels of IL-15 in plasma allows for the identification of a favorable outcome of STI.

Original language	English
Pages (from-to)	661-665
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	188
Issue number	5
DOIs	https://doi.org/10.1086/377454
Publication status	Published - Sep 1 2003

ASJC Scopus subject areas

Public Health, Environmental and Occupational Health
Immunology

Access to Document

10.1086/377454

Cite this

Amicosante, M., Poccia, F., Gioia, C., Montesano, C., Topino, S., Martini, F., Narciso, P., Pucillo, L. P., & D'Offizi, G. (2003). Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection. Journal of Infectious Diseases, 188(5), 661-665. https://doi.org/10.1086/377454

Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection. / Amicosante, Massimo; Poccia, Fabrizio; Gioia, Cristiana et al.

In: Journal of Infectious Diseases, Vol. 188, No. 5, 01.09.2003, p. 661-665.

Research output: Contribution to journal › Article › peer-review

Amicosante, M, Poccia, F, Gioia, C, Montesano, C, Topino, S, Martini, F, Narciso, P, Pucillo, LP & D'Offizi, G 2003, 'Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection', Journal of Infectious Diseases, vol. 188, no. 5, pp. 661-665. https://doi.org/10.1086/377454

@article{6d711d31a40d4c0c97d138ec340070c3,

title = "Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection",

abstract = "Structured treatment interruption (STI) may help to alleviate the problems associated with long-term antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients. We analyzed the role that baseline levels of cytokines in plasma play as markers of a favorable outcome of STI. Two groups of patients were defined: STI responders and STI nonresponders. STI responders showed a higher baseline concentration of interleukin (IL)-15 in plasma than did STI nonresponders and showed lower levels of tumor necrosis factor (TNF)-α during STI. No differences were observed in levels of IL-2, IL-7, or interferon-α in plasma. Our data show that (1) levels of TNF-α in plasma correlate with HIV viremia and (2) monitoring baseline levels of IL-15 in plasma allows for the identification of a favorable outcome of STI.",

author = "Massimo Amicosante and Fabrizio Poccia and Cristiana Gioia and Carla Montesano and Simone Topino and Federico Martini and Pasquale Narciso and Pucillo, {Leopoldo P.} and Gianpiero D'Offizi",

year = "2003",

month = sep,

day = "1",

doi = "10.1086/377454",

language = "English",

volume = "188",

pages = "661--665",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection

AU - Amicosante, Massimo

AU - Poccia, Fabrizio

AU - Gioia, Cristiana

AU - Montesano, Carla

AU - Topino, Simone

AU - Martini, Federico

AU - Narciso, Pasquale

AU - Pucillo, Leopoldo P.

AU - D'Offizi, Gianpiero

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Structured treatment interruption (STI) may help to alleviate the problems associated with long-term antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients. We analyzed the role that baseline levels of cytokines in plasma play as markers of a favorable outcome of STI. Two groups of patients were defined: STI responders and STI nonresponders. STI responders showed a higher baseline concentration of interleukin (IL)-15 in plasma than did STI nonresponders and showed lower levels of tumor necrosis factor (TNF)-α during STI. No differences were observed in levels of IL-2, IL-7, or interferon-α in plasma. Our data show that (1) levels of TNF-α in plasma correlate with HIV viremia and (2) monitoring baseline levels of IL-15 in plasma allows for the identification of a favorable outcome of STI.

AB - Structured treatment interruption (STI) may help to alleviate the problems associated with long-term antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients. We analyzed the role that baseline levels of cytokines in plasma play as markers of a favorable outcome of STI. Two groups of patients were defined: STI responders and STI nonresponders. STI responders showed a higher baseline concentration of interleukin (IL)-15 in plasma than did STI nonresponders and showed lower levels of tumor necrosis factor (TNF)-α during STI. No differences were observed in levels of IL-2, IL-7, or interferon-α in plasma. Our data show that (1) levels of TNF-α in plasma correlate with HIV viremia and (2) monitoring baseline levels of IL-15 in plasma allows for the identification of a favorable outcome of STI.

UR - http://www.scopus.com/inward/record.url?scp=0141724627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141724627&partnerID=8YFLogxK

U2 - 10.1086/377454

DO - 10.1086/377454

M3 - Article

C2 - 12934181

AN - SCOPUS:0141724627

VL - 188

SP - 661

EP - 665

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -

Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this